Incyte Corp stock (US45337C1027): Biopharma leader in oncology therapies.

{
  "signal_id": "1bbe8299-15fd-4272-a691-ca744b31dd76",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-05-14T00:00:00+00:00",
  "company": {
    "name": "Incyte",
    "domain": "incyte.com"
  },
  "data": {
    "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/incyte-corp-stock-us45337c1027-biopharma-leader-in-oncology-therapies/69336338",
    "title": "Incyte Corp stock (US45337C1027): Biopharma leader in oncology therapies.",
    "ticker": "NASDAQ:INCY",
    "excerpt": "Incyte Corp stock (US45337C1027): Biopharma leader in oncology therapies.\n\n14.05.2026 - 19:19:09 | ad-hoc-news.de\n\nIncyte Corporation, a key player in oncology and inflammation treatments, maintains a market cap of $19.74 billion with shares trading around $100 on Nasdaq. Recent data highlights its strong financials and institutional interest for US investors.\n\nIncyte Corporation continues to focus on developing novel therapies in oncology and inflammation, with key products driving revenue in the US market. The company reported a trailing P/E ratio of 13.96 and net margins of 26.71% for the latest period published on MarketBeat as of May 2026. Institutional holders like Dimensional Fund Advisors LP own 0.99% of shares.\n\nAs of: 14.05.2026\n\nBy the editorial team - specialized in equity coverage.\n\nAt a glance.\n\n* Name: Incyte Corporation\n* Sector/industry: Medical / Biotechnology\n* Headquarters/country: Wilmington, Delaware, USA\n* Core markets: US and global oncology\n* Key revenue drivers: Oncology therapies\n* Home exchange/listing venue: Nasdaq (INCY)\n* Trading currency: USD\n\nOfficial source\n\nFor first-hand information on Incyte Corp, visit the company's official website.\n\nIncyte Corp: core business model.\n\nIncyte Corporation specializes in the discovery, development, and commercialization of therapies targeting oncology and inflammation. Headquartered in Wilmington, Delaware...",
    "product": "novel therapies in oncology and inflammation",
    "summary": "Incyte Corporation is developing novel therapies in oncology and inflammation.",
    "location": "United States, Northern America, Americas",
    "planning": false,
    "image_url": "https://mdb.ad-hoc-news.de/bild/bild-2405048_1200_800.webp",
    "confidence": 0.4666,
    "product_data": {
      "full_text": "novel therapies in oncology and inflammation",
      "fuzzy_match": true
    },
    "published_at": "2026-05-14T00:00:00Z",
    "location_data": [
      {
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "article_sentence": "Incyte Corporation continues to focus on developing novel therapies in oncology and inflammation, with key products driving revenue in the US market."
  }
}

curl https://signals.autobound.ai/v1/signals/1bbe8299-15fd-4272-a691-ca744b31dd76 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"incyte.com","limit":20}'